CLRT: Launch of New Gene Expression Test for Prostate Cancer
CLRT: Launch of New Gene Expression Test for Prostate Cancer
Tue. January 13, 2009; Posted: 08:08 AM

Ridgeland, MS, JAN 13, 2009 (EventX/ via COMTEX) -- HDVY | Quote | Chart | News | PowerRating -- By Fain Hughes,
Clarient, Inc. (CLRT) announced the commercial launch of its new gene expression test for prostate cancer. This new test will be available through Clarient's PATHSiTE(TM) virtual reporting tool and accessible to the company's entire pathology network

Clarient's new test is based on a unique and patent protected combination of four genes that have been shown to accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells in prostate tissue. The association of these four genes with prostate cancer was discovered by Health Discovery Corporation (HDVY) using their patented SVM and SVM-RFE pattern recognition technology.

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

If your company wishes to participate in the EventX newswire, please contact Knobias:, LLC 601-978-3399 601-978-3675

For full details for CLRT click here.
Comments: 0